HeartBeam(BEAT) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For the full year 2025, the net loss was $21 million or $0.62 per share, while the fourth quarter net loss was $5.3 million or $0.15 per share, aligning with expectations [28] - Net cash used in operating activities was less than $14 million for the full year and just $2.9 million for the fourth quarter, representing a 3% decrease year-over-year and a 30% decrease compared to the same quarter last year [28][29] - Cash and cash equivalents totaled $4.4 million at December 31, 2025, with access to capital markets remaining strong [29] Business Line Data and Key Metrics Changes - HeartBeam's core technology includes a portable cable-free ECG that synthesizes a 12-lead ECG, with FDA 510(k) clearance achieved for arrhythmia assessment [5][6] - The company is launching a second form factor, an on-demand 12-lead extended wear patch, which is expected to disrupt the $2 billion ambulatory cardiac monitoring market [8][20] - The initial commercial launch is focused on concierge and preventive cardiology practices, targeting a price per patient of $500-$1,000 per year [11][12] Market Data and Key Metrics Changes - The target market includes approximately 1.5 million Americans currently paying for concierge medicine, with a focus on high-net-worth individuals who show a strong willingness to adopt advanced health technology [11][12] - The company aims to capture a small portion of the concierge market initially, with plans to expand into larger patient segments, including direct primary care practices and telehealth networks [12][13] Company Strategy and Development Direction - HeartBeam's strategy involves a staged approach to commercialization, starting with a limited launch in concierge cardiology and executive health [13][16] - The company plans to validate its model in a concentrated market before scaling, with a focus on deep adoption within initial practices [12][16] - The collaboration with Mount Sinai aims to enhance AI capabilities and bring advanced algorithms to the HeartBeam device [25][98] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for the HeartBeam system, highlighting the strong interest from both patients and physicians [10][11] - The company anticipates significant advancements in 2026, with ongoing studies and product launches expected to drive growth [32][34] - The management emphasized maintaining financial discipline while advancing key milestones and developing the R&D pipeline [28][29] Other Important Information - The HeartBeam 12-lead patch is expected to provide better diagnostic capabilities and integrate into existing workflows, leveraging existing reimbursement [20][21] - The company has completed a working prototype of the patch and is conducting clinical studies to validate its effectiveness [23][26] Q&A Session Summary Question: Can you talk about the timeline for the ALIGN pilot study and the patch initiatives? - Management indicated that the ALIGN-ACS pilot study is expected to enroll quickly due to its design, with completion anticipated by the end of Q3 2026 [36][39] Question: What does the account pipeline look like for the commercialization strategy? - The focus is on a limited number of anchor accounts initially, with plans to validate the premium value proposition before scaling [41][43] Question: How should we think about R&D expenses trending in the upcoming quarters? - R&D expenses are expected to step up slightly in the first half of the year due to clinical trials, then return to baseline levels [49][51] Question: Can you provide details on the Mount Sinai relationship and potential for similar alliances? - The relationship with Mount Sinai was built on mutual respect and shared goals in advancing AI algorithms for ECG data, with openness to future partnerships [96][98]